GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) carry the clinical evidence: STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
At Renew Health & Wellness, we offer semaglutide as part of a medically guided weight loss approach designed to address these underlying challenges
We will explain treatmentlike options, peels, lasers, and aftercare
Ready to find relief
Similarly, high salt intake forces the kidneys to excrete more calcium into the urine
However, the characteristic hyperandrogenism the primary reproductive phenotype of PCOS results from excess ovarian androgen production (Fig